Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 evaluation of trientine in hypertrophic cardiomyopathy
2020-002242-17Phase 2Unknown
- Sponsor
- Manchester University NHS Foundation Trust
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Trientine (Cufence) with Placebo (2 arms). Primary endpoint: Change in left ventricular mass index. Status: unknown.
02
Drugs
trientine
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2020-002242-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002242-17.